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ABSTRACT

Objective: ATP1A3-related neurologic disorders encompass a broad range of phenotypes that
extend well beyond initial phenotypic criteria associated with alternating hemiplegia of childhood
(AHC) and rapid-onset dystonia parkinsonism.
Methods: In 2014, the Alternating Hemiplegia of Childhood Foundation hosted a multidisciplinary
workshop intended to address fundamental challenges surrounding the diagnosis and management of individuals with ATP1A3-related disorders.
Results: Workshop attendees were charged with the following: (1) to achieve consensus on expanded
diagnostic criteria to facilitate the identification of additional patients, intended to supplement existing
syndrome-specific diagnostic paradigms; (2) to standardize definitions for the broad range of paroxysmal manifestations associated with AHC to disseminate to families; (3) to create clinical recommendations for common recurrent issues facing families and medical care providers; (4) to review data related
to the death of individuals in the Alternating Hemiplegia of Childhood Foundation database to guide
future efforts in identifying at-risk subjects and potential preventative measures; and (5) to identify critical gaps where we most need to focus national and international research efforts.

Conclusions: This report summarizes recommendations of the workshop committee, highlighting the
key phenotypic features to facilitate the diagnosis of possible ATP1A3 mutations, providing recommendations for genetic testing, and outlining initial acute management for common recurrent clinical
conditions, including epilepsy. Neurol Genet 2017;3:e139; doi: 10.1212/NXG.0000000000000139
GLOSSARY
AHC 5 alternating hemiplegia of childhood; AHCF 5 Alternating Hemiplegia of Childhood Foundation; CAPOS 5 cerebellar
ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss; NGS 5 next-generation sequencing; RDP 5 rapidonset dystonia parkinsonism; SUDEP 5 sudden unexpected death in epilepsy; WES 5 whole-exome sequencing.

Na1/K1 adenosine triphosphatases (sodium/potassium pumps) are P-type cation transport
proteins that establish and maintain electrochemical gradients for Na1 and K1 across the plasma
membrane. Mutations in the a3 catalytic subunit, encoded by ATP1A3, which in the nervous
system is exclusively expressed in neurons, are associated with at least 3 distinct, yet overlapping,
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neurologic syndromes: rapid-onset dystonia
parkinsonism (RDP); alternating hemiplegia
of childhood (AHC); and cerebellar ataxia,
areflexia, pes cavus, optic atrophy, and sensorineural hearing loss (CAPOS). From the past
descriptions of each entity, distinct phenotypes have emerged, demonstrating that classic
AHC, classic RDP, and CAPOS syndrome
constitute clinical prototypes in a continuous
and still expanding phenotypic spectrum of
ATP1A3-related disorders.
In June of 2014, an international consortium of experts consisting of neurologists, epileptologists, clinical geneticists, genetic
counselors, physiatrists, physical therapists, psychologists, basic scientists, and foundation representatives convened in Minneapolis, MN, in
conjunction with the Alternating Hemiplegia
of Childhood Foundation (AHCF) International Family Meeting. A series of quarterly teleconferences performed in the year preceding
the conference, including representatives from
the AHCF parent advisory board and supplemented by online queries to parents via online
discussion boards, were used to identify key issues and points of concern from the parent/
caregiver perspective. An initial expert panel
discussion and multidisciplinary workshop
were followed by the selection of a task force assigned to specific key areas to further refine and
revise materials over the course of the subsequent 18 months. The following article serves
as a research conference summary initiated at
the AHCF International Family Meeting.
Workshop attendees focused efforts on the
following aims: (1) to reach consensus on an
expanded diagnostic paradigm for identifying
patients with an ATP1A3-related neurologic
disorder to supplement existing syndromebased diagnostic criteria; (2) to develop standardized definitions for types of episodic
manifestations associated with AHC, the most
complex of the ATP1A3-related neurologic
phenotypes and to disseminate these among
families; (3) to create initial clinical recommendations for recurrent issues facing families and
medical care providers; (4) to review deaths in
the AHCF database to guide future efforts in
identifying at-risk subjects and potential preventative measures; and (5) to identify critical
gaps where the AHC research community most
2
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needs to focus national and international efforts. The primary goal of these efforts is to
promote additional reviews and discussions
among the broader international community
of clinicians, scientists, and family support organizations in anticipation of the robust infrastructure needed for future collaborative clinical
studies and trials. In particular, natural longitudinal history data are critically needed to identify end points necessary to assess the benefit of
new treatments. Our work here admittedly
focused on those on the more severe end of
the spectrum of ATP1A3-related disorders
within developed countries. However, ATP1A3-related disorders clearly affect patients
of all ages, races, and ethnicities. Continued
efforts to enroll patients in registries worldwide
to better understand both phenotypes and outcomes remains an important goal.
CONSENSUS TOWARD AN EXPANDED NON–
SYNDROME-BASED DIAGNOSTIC ALGORITHM FOR
ATP1A3-RELATED
NEUROLOGIC
DISORDERS

Numerous publications over the past 4 decades
have described and subsequently refined clinical
diagnostic criteria for what are now recognized to
be ATP1A3-related disorders, beginning with the
original description of AHC in 19711 followed by
RDP in 19932 and of CAPOS in 1996.3 Mutations
in ATP1A3 were identified as the genetic cause of
RDP in 2004.4 It was not until 2012 that de novo
mutations in ATP1A3 were found in the majority of
patients with AHC.5,6 In 2014, a novel recurrent
mutation in ATP1A3 was identified in patients with
CAPOS.7 Since then, an increasing number of
atypical cases with ATP1A3 mutations have been
identified spanning the phenotypic spectrum between
AHC, RDP, and CAPOS syndromes, creating
controversy as to whether these disorders should be
considered discrete syndromes or points along
a broadly heterogeneous spectrum.8–13
The identification and description of distinct neurologic syndromes has served as a critical point of reference to help clinicians identify and study rare
patient populations in the absence of a clear molecular etiology. Prior to 2004 in RDP and 2012 in AHC,
expert consensus–developed clinical criteria served as
the primary pathway to diagnosis. More recently,
important genotype-phenotype correlations relating
to individual mutations have begun to emerge in ATP1A3-related neurologic disorders. We await to see
whether genotype-phenotype correlations hold up
over time with the accrual of new patient cohorts
identified in the context of an unbiased nextgeneration sequencing–based approach.

Members of the task force attempted to provide
a more comprehensive diagnostic approach than was afforded under previous clinical criteria. This would allow
for clinicians to go beyond existing core phenotypic
components in identifying ATP1A3-related disorders.
As a starting point, we compiled diagnostic criteria for
AHC and RDP and clinical features of CAPOS, inclusive of previously suggested supporting features based on
the available literature (table 1). Next, we sought consensus on a new diagnostic paradigm that focused on

Table 1

major and minor neurologic symptoms or signs that
broadly supported an association with mutations in ATP1A3 in the absence of a context of a specific syndrome
(table 2). A brief summary of each disorder is provided
below, highlighting important features both shared and
distinct among the 3 syndromes. Table 3 reviews the
differential diagnosis of disorders with overlapping signs
and symptoms.
Classic AHC. Since the discovery of ATP1A3 as the
causative mutation in the majority of AHC cases,5,6 at

Compilation of previously published diagnostic criteria for AHC, RDP, and CAPOS syndromes
Features supportive for CAPOS
syndromec

Diagnostic criteria for AHCa

Diagnostic criteria for RDPb

1. Onset of paroxysmal symptoms before
age 18 mo

1. Onset of dystonia 1 Parkinson disease 1. Cerebellar ataxia
over a few minutes to 30 d

2. Repeated attacks of hemiplegia that
alternate in laterality

2. A clear rostrocaudal gradient of
involvement (face . arm . leg)

2. Areflexia

3. Episodes of quadriparesis or plegia as a
separate attack or as generalization of a
hemiplegic event

3. Prominent bulbar findings on
examination

3. Pes cavus (not universally
present)

4. Other paroxysmal symptoms including
dystonic spells, oculomotor abnormalities, or
autonomic symptoms either concurrent with
hemiplegic attacks or independently

4. Absence of response to an adequate 4. Optic nerve atrophy
trial of L-dopa therapy (e.g., carbidopa/
levodopa 25/100 mg, 1 pill 33/d)

5. Relief from symptoms upon sleep

5. Family history consistent with
autosomal dominant inheritance but
de novo mutations increasingly well
documented

5. Sensorineural hearing loss

6. Evidence of developmental delay or
neurologic findings such as choreoathetosis,
dystonia, or ataxia
Additional features supporting an
Additional features supporting an AHC diagnosis RDP diagnosis
a. Repeated attacks of monocular nystagmus

a. Minimal or no tremor at onset

b. Normal neuroimaging in the presence of
fluctuating but persistent neurologic deficits,
especially paresis or dystonia

b. Occasional mild limb dystonia prior to
the abrupt onset of dystonia

c. EEG recording during typical episodes of
persistent motor dysfunction fails to show
electrographic
seizure activity

c. Often associated with triggers (e.g.,
running, childbirth, emotional stress, or
alcoholic binges) associated with the
abrupt onset of symptoms

d. Stepwise deterioration in motor, cognitive or
speech, and language functions following
a prolonged episode, in the setting of ongoing
paroxysmal motor signs and symptoms

d. Stabilization of symptoms within
a month

e. Development of new fixed deficits with
a rostrocaudal gradient of severity, resulting in
persistent oromotor dystonia and dysarthria

e. Rare “second onsets” or abrupt
worsening of symptoms later in life

f. Lack of family history (due to high
prevalence of de novo mutations) or family
history consistent with dominant inheritance

f. Minimal improvement overall but with
limited improvement in gait

Atypical features

Atypical features

1. Onset over age 18 mo

1. Onset over age 60 y

2. Obvious structural abnormalities on
neuroimaging studies at initial presentation

2. Onset of seizures after the
appearance of motor symptoms
3. Rapid-onset ataxia with cerebellar
atrophy

Abbreviations: AHC 5 alternating hemiplegia of childhood; CAPOS 5 cerebellar ataxia, areflexia, pes cavus, optic atrophy,
and sensorineural hearing loss; RDP 5 rapid-onset dystonia parkinsonism.
a
Adapted from references 14, 33, 38, and 39.
b
Adapted from references 2, 16, 20, 40, and 41.
c
Adapted from reference 7.
Neurology: Genetics
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Table 2

Major and minor features supporting ATP1A3 molecular analysis

Age at onset

Major (highly suggestive pathognomonic
features)

Infancy and early childhood Alternating hemiparesis, plegia, or dystonia

Child or adult-onset

Appearance at any age

Minor (supportive but less-specific
features)
Paroxysmal irritability, crying

Paroxysmal episodes of monocular
nystagmus 6 other motor signs or symptoms

Persistent or fluctuating oculomotor abnormalities,
including strabismus and nystagmus

Paroxysmal conjugate or dysconjugate ocular
movement abnormalities

Autonomic disturbances: apnea, color change or
mottling, or temperature change of the affected
limb(s), temperature instability, or pupillary
abnormalities (i.e., dilated or poorly reactive pupil)

Acute flaccid quadriparesis persisting for
hours to days

Fluctuating or paroxysmal generalized hypotonia

Recurrent paroxysmal tonic or dystonic
“seizure-like” episodes

Developmental regression related to a long-lasting
episode

Paroxysmal onset of ataxia, which becomes
fixed or remains episodic

Behavioral manifestations including aggression
toward self or others

Paroxysmal dystonia or hemidystonia

Mood disorders including depression, social
phobia, anxiety, bipolar disorder, and psychosis

Acute, fluctuating motor function deficits
persisting for hours to days, including ataxia,
chorea, hemiplegia, or paresis

Acute or subacute onset of encephalopathy or
fluctuating mental status 6 motor signs

Paroxysmal episodes of motor signs with EEG
monitoring documenting the absence of
epileptiform activity

Rapid fluctuations in mood and irritability

Episodes clinically consistent with
generalized or focal epilepsy (with or
without ictal EEG)

Persistence of oculomotor abnormalities including
strabismus or ophthalmoparesis

Normal brain MRI in the setting of
acute-onset or recurrent episodes of
neurologic impairment

Sensorineural hearing loss

Asymmetric paroxysmal onset of hemiplegia or
paresis, quadriplegia or paresis, spasticity,
dystonia, and dyskinesia, with or without the
subsequent appearance of fixed neurologic
deficits

Delayed acquisition or stepwise deterioration in
cognitive, fine and gross motor, and speech and
language skills

Rostrocaudal gradient (topographic, not
temporal) of fixed or fluctuating motor
involvement

Features consistent with clinical diagnosis of
epilepsy, with or without corroborating EEG
evidence

Multiple environmental triggers, ranging from
physical exertion, extremes of temperature,
emotional stimuli (excitement, fear), and
chemical (foods, smells)

Sensorineural hearing loss

Seizure-like paroxysmal tremor affecting one or Acquisition, either acutely or subacutely, of static
more limbs or inclusive of whole body tremors, neurologic signs including ataxia, choreoathetosis,
shivering
dystonia, eye movement abnormalities, or
parkinsonism
Paroxysmal bulbar symptoms (dysarthria/
dysphagia), with or without resolution over
hours to days

Resolution of symptoms with sleep

Suspected epileptic event with negative EEG
recording during a typical spell, especially if
associated with tonic or dystonic posturing or
migratory paresis

Negative family history or family history
suggesting dominant inheritance

Normal brain MRI in the setting of either acute Fluctuating autonomic symptoms and signs
onset of new neurologic symptoms or recurrent
episodes of neurologic impairment

least 34 unique mutations have been identified.14
AHC is characterized by recurrent episodes of paroxysmal hemiplegia, dystonia, ocular movement abnormalities (monocular nystagmus and deviation),
autonomic dysfunction, as well as developmental
delay. With increasing age, many patients ultimately
manifest epilepsy; however, the characteristic presentation in infants includes a variety of episodic, nonepileptic tonic, dystonic, or plegic (weakness) spells
4
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that often are refractory to treatment with most therapeutic agents. The early onset and rapidly evolving
clinical signs and symptoms frequently contribute to
diagnostic delays. The relatively broad differential
diagnosis (table 3) and the lack of a specific genetic
test prior to 2012 resulted in a widely variable
approach to attempts to treat paroxysmal events
(often presumed to be seizures even in the absence
of electrophysiologic evidence). While the most

Table 3

Differential diagnosis of ATP1A3-related disorders and molecular etiology

Differential diagnosis of ATP1A3-related disorders

Molecular pathogenesis

Glut-1–deficiency syndrome (OMIM #606777)

GLUT1

Mitochondrial disorders, e.g., Leigh syndrome,
MERRF, PDH deficiency, POLG1, and others
(OMIM #25600, #545000, #312170, and
#174763)

Numerous mitochondrial and nuclear
genome pathogenic variants

Familial hemiplegic migraine syndromes (FHM1,
OMIM #141500; FHM2, OMIM #60248; and
FHM3, OMIM #609634)

CACNA1A, ATP1A2, and SCN1A

Dystonic cerebral palsy
Infantile-onset epilepsy syndromes including
Dravet

SCN1A

Other epilepsy syndromes with Todd paralysis
Defects in neurotransmitter biosynthesis and
metabolism, i.e., Segawa disease, aromatic amino
acid decarboxylase deficiency, tyrosine
hydroxylase deficiency, dihydropteridine reductase
deficiency, sepiapterin reductase deficiency,
6-pyruvoyl-tetrahydropterin synthase deficiency

GCH1, AADC, TH, QDPR, SPR, and
PTS

Other complex movement disorder phenotypes,
including myoclonus dystonia

SCGE, KCTD17, and others

pathognomonic events include hemiplegic or hemidystonic episodes that affect either side of the body,
children also frequently have bilateral involvement,
including generalized fluctuating dystonia, quadriplegia, or paresis of variable duration.
A variety of nonparoxysmal symptoms and signs
become increasingly evident with age, including
global developmental delays; behavioral, attentional,
and executive dysfunction with variable intellectual
disability; dysarthria, ataxia, chorea, dystonia, and,
less frequently, pyramidal tract signs such as spasticity
and hyperreflexia. To date, we have limited data on
the full spectrum of the burden of acquired neurologic deficits in this population; more robust longitudinal data are needed.
Rapid-onset dystonia parkinsonism. In 2004, it was

demonstrated that heterozygous mutations in the ATP1A3 gene are causative of RDP.4 Since then, at least
14 mutations have been identified.4,9,15–19 Clinical
hallmarks of RDP include the abrupt onset of bulbar
symptoms and limb dystonia with features of parkinsonism (bradykinesia and postural instability) that
exhibit limited progression over weeks and little
change thereafter. Dystonic symptoms typically
show minimal response to L-dopa or dopaminergic
agonists. The severity of acquired neurologic signs
and symptoms demonstrates a rostrocaudal gradient
of involvement (face . arm . leg). Disease onset has
been reported between the ages of 4 and 58 years.
Symptoms can be triggered by a broad range of physical, emotional, or chemical triggers. Beyond dystonia
and parkinsonism, several patients with classic RDP
display other symptoms including depression and

anxiety/social phobia. A minority of patients develop
seizures years after the disease onset. The diagnostic
criteria for RDP were revised in 2007.20 Major
and minor diagnostic criteria for RDP are summarized in table 1.
CAPOS syndrome. The constellation of CAPOS was
first described as a unique clinical entity in 1996.3 To
date, very few patients have been described with this
syndrome and no information about prevalence and
incidence is available. The combination of the aforementioned symptoms is characteristic of this syndrome,
although these do not constitute diagnostic criteria,
given the limited number of cases. A single recurrent
missense mutation in ATP1A3 (c.2452G.A;
Glu818Lys) has been identified in all cases to date.21
Of note, only 5 of 18 identified patients exhibit pes
cavus, and a full spectrum of manifestations is likely
broader.7,21–23
The identification of an increasing number of patients with mutations in the ATP1A3 gene and phenotypic overlap of the above-mentioned diseases
demonstrates that classic AHC, classic RDP, and
CAPOS syndrome constitute clinical prototypes of
a continuous phenotypic spectrum from ATP1A3related disorders.24
Updating the current syndrome-based diagnostic
algorithm using criteria outlined in table 1, with
one emphasizing the presence of the key major
(pathognomonic) and minor (supporting) signs and
symptoms (table 2), is intended to focus attention on
the rapidly evolving spectrum of ATP1A3-related disorders for clinicians and families. Ideally, this dual
approach will facilitate the earliest possible identification of the primary genetic defect in patients presenting a wider phenotypic spectrum. This will reduce the
often prolonged diagnostic odyssey and facilitate prospective enrollment into clinical studies designed to
help better understand the natural history of the
disorder.

STANDARDIZED DEFINITIONS FOR PAROXYSMAL
EVENTS IN AHC The complex and variable paroxys-

mal events in AHC result in challenges in defining aspects of the ATP1A3-related disorders. Currently,
neither families nor clinicians use a unified set of definitions to guide them when they attempt to communicate the frequency, duration, and overall effect of
types of episodes their child may be experiencing. It
is often not clear to families or their clinicians how they
should categorize episodes that may or may not be
seizures or some other complex movement disorders.
Not only does this result in an inconsistent approach
among both caregivers and clinicians, it makes it more
challenging for parents to determine what constitutes
an emergency for which they should seek additional
Neurology: Genetics
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Table 4

Proposed nomenclature for simplified episode description in alternating hemiplegia of childhood

Primary episode
name
Hemi-body episode

Episode description

Episode subtypes

An event involving one or more limbs on the same
side of the body; episodes may or may not include
abnormal eye movements or other additional
features; if sides switch during an episode but the
original affected side recovers, it is considered
a continuation of the same episode

1. Hemiplegic/hemiparetic—limbs paralyzed or weak

2. Dystonic—limbs or body stiff but with involuntary
posturing, i.e., stuck into a particular position, head
and neck often turned or extended
Full-body episode

Any event in which the 2 sides of the body are
1. Quadriplegia or quadriparesis—all 4 limbs with
affected at the same time; if the right arm and left
loss of tone and weakness or paralysis, often
leg are affected at the same time, it is coded as
associated with loss of speech and altered
“full-body”; if transient full-body weakness occurs when
breathing
hemiparetic episodes switch sides, it would only be
coded as full-body if both sides are affected for .5 min
2. Tonic—all 4 limbs in sustained extension
3. Dystonic—all 4 limbs stiff but twisted into unusual
postures, often associated with head turning or
head and neck extension. Individual is conscious
and may appear to be in significant pain or distress

Seizure-like episode Any episode in which the patient seems to be
unresponsive or unconscious, with or without the
following features: repetitive jerking or whole body
stiffening or tonic-clonic activity with rhythmic
jerking movements, or whole body trembling or
twitching movements

1. Tonic-clonic (repetitive jerking movements
involving one or more limbs in focal vs whole body
in generalized)

2. Tonic (stiffening of part of a whole body)
3. Myoclonic (lightening-like jerking movements)
4. Complex-partial (confused behavior with inability
to follow commands, often in association with
more complex behaviors)
5. Absence—brief episodes of unresponsiveness,
often in association with brief cessation of motor
activity
6. Atonic—sudden loss of whole body tone, resulting
in “drop-attacks”

urgent medical assistance. Table 4 presents a simplified
nomenclature using a language more accessible for
caregivers to document events in a way that might be
valuable in the context of longitudinal studies or clinical trials.
CATASTROPHIC EVENTS IN ATP1A3-RELATED
DISORDERS Over the course of the past 2 decades,

4 of 187 (2%) prospectively enrolled patients in the
US/International AHCF registry with documented
pathogenic mutations in ATP1A3 and clinical features
consistent with AHC have died, many of them unexpectedly, with or without an apparent antecedent
stressor. Three scenarios have emerged that deserve
additional attention in terms of focused research, prevention strategies, and clinical management recommendations: (1) the sudden acquisition of newly
acquired, nonparoxysmal severely disabling neurologic
deficits, representing a substantial lasting change in the
neurologic status in a previously stable patient, (2) the
appearance of increasingly refractory epilepsy or bilateral dystonia and status epilepticus or status dystonicus, and (3) sudden unexpected death, with or without
6
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an obvious antecedent stressor. Admittedly, the literature regarding these scenarios, as well as potential
causes and/or interventions, is essentially nonexistent.
Table 5 lists age, ATP1A3 mutation, associated clinical
features, perimortem circumstances, and systemic
pathology data for the 4 patients with AHC.
The sudden acquisition of new and severely disabling neurologic deficits in patients with AHC, particularly dystonia, has many parallels with the acute or
subacute acquisition of evolving neurologic deficits
initially described in patients with RDP.20 However,
in patients with AHC, these deficits occur in the
context of an already established syndrome of paroxysmal AHC symptoms and neurodevelopmental deficits, making it initially less obvious that any episode
may ultimately prove irreversible. Our understanding
of the critical trigger(s) for such irreversible transformations remains unclear, since antecedent events
often appear no different from hundreds of prior episodes these children may have already experienced.
Sudden unexpected death in epilepsy (SUDEP) has
demanded increasing attention on the part of families
and practitioners within the epilepsy community and

ATP1A3 mutation, associated clinical features, perimortem circumstances, and systemic pathology data in 4 deceased patients with
AHC

Table 5

M/ Age,
F
y

ATP1A3
genotype Additional clinical features

Kindred

ID

Perimortem circumstances

Etiology

Autopsy findings (systemic)

K5011

32098 F

24

D801N

Classic AHC phenotype from
early infancy. Overall, high
level of social function;
increase in headache and
seizure frequency in the
months preceding her death.
Some new episode types that
she described as “throat
closing up” and “painful chest
spasms”; carbamazepine
dosage increased 1 month
prior; no hemiplegic spells the
month prior and no seizures
the day prior to her death

Found dead in bed following
an uneventful day in which
she had no apparent
indication of illness

Autonomic storm with
neurogenic pulmonary
edema?

Severe pulmonary edema;
thickened opacified mitral
valve; mild thickening of the
endocardium of the left
ventricle

K5126

32763 F

15

E815K

Classic AHC phenotype from
early infancy; walked
independently by 2 y; spoke in
2-word sentences by age 5 y;
significant regression at age
10 y in the setting of
adenovirus and encephalitis,
after which she developed
intractable complex-partial
epilepsy, permanent dysarthria,
dystonia, dyskinesia, and
marked worsening of behavior

Increasing seizure frequency
in the months preceding her
death, resulting in refractory
status epilepticus; intensive
care unit course complicated
by Hashimoto thyroiditis, and
metabolic abnormalities,
including hyperammonemia,
and hypercalcemia

Ventilatory support
voluntarily withdrawn in
the setting of
neuroimaging, indicating
severe brain injury

Pneumonia and changes
consistent with aspiration;
dystrophic calcification of
lungs and renal tubules;
hepatomegaly and hepatic
congestion; muscle with type
IIb fiber atrophy

K6415

39587 F

24

P808L

Classic AHC symptoms
presenting in infancy; frequent
hemiplegic events during early
childhood, which evolved to
less frequent events in her
teen years and emergence of
some intermittent headaches;
Relatively high functioning,
without persistent motor
deficits between episodes;
very social; and obesity

Prolonged dystonic
quadriplegia off and on the
day preceding the event, with
“chest twitching”; received
rectal valium before bedtime;
unwitnessed death in sleep,
found face down, and
incontinence of urine

Autonomic storm with
neurogenic pulmonary
edema

Generalized pulmonary
edema; fatty right ventricle
but normal thickness; mild
dilatation of the left ventricle
and thinning of the ventricular
wall near the apex; and
microscopic examination of
heart reveals disarray and
hypertrophic fibers

K30781 95438 M

31

G947R

Classic AHC symptoms
presenting in infancy. History
of epilepsy with grand mal
seizures. One hospitalization
for status epilepticus requiring
induced coma 2 y prior to
death, with the subsequent
worsening of dysarthria,
cognitive function, and
impaired motor coordination.
Significant initial response to
flunarizine, resulting in 169
d without “bilateral” dystonia

Had been in the usual state of
health, on vacation with
caregivers; overindulged in 6
snack-sized bags of “Cheetos”.
Developed nausea and
vomited once before bed;
seemed okay when he went to
bed a bit later than usual

Unwitnessed death
during sleep; found lying
on his side with poor
color, small amount of
bright red blood at
mouth, and gurgling after
death

Left ventricular concentric
hypertrophy without evident
infarct; lung parenchyma
congested with one focus of
aspiration

Abbreviation: AHC 5 alternating hemiplegia of childhood.

is the leading cause of death in the absence of status epilepticus or seizure-related trauma.25 A widely accepted
definition for SUDEP is included in table e-1 at
Neurology.org/ng.26 Proposed risk factors include the
use of multiple anticonvulsants, poor medication compliance, uncontrolled seizures, and the presence of
additional neurologic deficits, in addition to epilepsy,
among others.27
In light of the heightened awareness that certain
molecular etiologies may predispose to an increased risk
of sudden death,28 it should be emphasized that ATP1A3-related disorders may have a similar association,
both in the presence and absence of comorbid epilepsy.
ATP1A3 is expressed in human cardiac tissue,29 and
faulty cardiac repolarization has been demonstrated in
patients with AHC.30 Repetitive brief asystole was
documented in an individual with a confirmed

ATP1A3 mutation and AHC.31 Finally, as illustrated
in table 5, 3 patients prospectively enrolled in the
AHCF registry who died suddenly had documented
evidence of cardiac structural abnormalities, including
ventricular hypertrophy, on autopsy studies. In trying
to understand and prevent sudden death in ATP1A3related neurologic disorders, it is important to create
appropriate evidence-based recommendations regarding initial evaluation and long-term monitoring of cardiac status.
CRITICAL GAPS IN OUR CURRENT KNOWLEDGE
OF ATP1A3-RELATED DISORDERS Children who

present acutely with dystonia, encephalopathy, or
ataxia in the absence of pathognomonic features of
classic AHC (i.e., alternating weakness or dystonia)
account for an increasing proportion of ATP1A3
Neurology: Genetics
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mutation–positive cases. The prognosis for children
with variants of uncertain significance or for those
who have a variant with known low frequency is
uncertain, resulting in increased concern for both
parents and clinicians.
Even in patients with AHC presenting with a classic classic presentation in the context of one of the
common mutations, we have very limited information on long-term outcome with these disorders. This
is due to (1) lack of rigorous longitudinal natural history follow-up, (2) the relatively recent identification
of the primary genetic defect in AHC and CAPOS,
(3) delays in clinical awareness/implementation of
molecular testing, and (4) the enormous variability
of episodes and the absence of standardized measurement tools. The development of such tools is critical
in quantifying disease burden and ideally would allow
us to accurately represent episode type, frequency,
and severity and the subsequent influence on cognition, mood and behavior, language, bulbar function,
gross and fine motor function, activities of daily living, and quality of life.
Disease progression in subsets of ATP1A3-related
disorders associated with fluctuating neurologic signs
and symptoms is often hard to appreciate, in that
symptoms follow a waxing/waning course that may
result in increasing difficulty (and parental fatigue) in
complying with routine clinic visits. Children may
gradually fall behind in development relative to their
peers, or repeatedly lose then regain skills, making
acquired accumulated and progressive neurologic deficits not immediately obvious. As children get older,
caregivers often become increasingly reluctant to use
the urgent care setting when new events occur
because knowledge and tools are ineffective and lasting solutions to understand and manage these complex events are not yet available.
Over time, documenting the frequency and course
of events may seem overwhelming and futile to primary caregivers. Physicians, likewise, become discouraged when imaging tests, EEGs, and laboratory
testing repeatedly fail to provide answers or guidance
for management. As an example, when a new type of
paroxysmal event appears, it may initially be considered a variation of a previously documented complex
nonepileptic movement disorder rather than a possible
seizure. Appropriate intervention may, thus, be delayed when overt seizures finally manifest, resulting
in potentially catastrophic outcomes such as death
or acquisition of new permanent neurologic deficits
in the setting of status epilepticus.
There may be important variations in phenotypic
severity among patients with the most common
ATP1A3 mutations affecting “hot spots” in exons 17,
18, and 21.9 Initial data from patients with AHC with an
E815K mutation demonstrated more severe impairment
8
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in motor function, intellectual disability, and epilepsy.14,32 Moving forward, development of standardized
multicenter databases would allow rigorous monitoring,
and documentation of clinical disease evolution should
help permit us to more accurately capture mutationspecific differences with prognostic implications.
In many disorders, tools such as motor function
scales, timed tests, and neuropsychological tools,
including age-appropriate assessments of executive
and cognitive function, mood, and behavior, can be
standardized for use across patient cohorts. Unfortunately, the fluctuating nature of AHC symptoms in
many children makes standardized motor and cognitive function tests more challenging to use than in
other more static or progressive neurologic disorders.
Therefore, a focus on caregiver-reported outcomes or
a measure of overall functional assessment of patients
in performing daily self-care tasks may be more practical in this setting.
SUGGESTED ACUTE MANAGEMENT RECOMMENDATIONS FOR COMMONLY ENCOUNTERED
ADVERSE EVENTS IN PATIENTS WITH ATP1A3RELATED DISORDERS During the workshop,

members attempted to identify the most common
and challenging clinical scenarios encountered in
the acute care setting. As yet, these issues are largely
underaddressed in the existing literature. It was
agreed that action plans for certain commonly
encountered issues could help standardize approaches
in the acute setting. These recommendations could be
an invaluable tool to facilitate communication
between primary caregivers and physicians when they
seek urgent care for their child with an ATP1A3related neurologic disorder. They may help streamline
discussions with health care providers and minimize
the risk of adverse complications. We have created
initial drafts for action recommendations (see supplemental materials) to address 3 recurring clinical scenarios frequently involving affected children or
adults: (1) increasingly frequent and painful dystonic
crises or status dystonicus, (2) new signs or symptoms
thought to be clinically consistent with epilepsy or
status epilepticus, and (3) recurring behavioral crises
constituting a danger to self or others.
RECOMMENDATIONS FOR MOLECULAR DIAGNOSTIC TESTING Both AHC and RDP phenotypes

can be associated with de novo mutations or dominant
inheritance within families, although the vast majority
of patients with AHC identified to date have de novo
mutations. Because neurologic symptoms and signs
associated with ATP1A3-related disorders overlap with
many other neurologic syndromes, the ATP1A3 gene
has been increasingly included in next-generation
sequencing (NGS) panels for epilepsy, ataxia, and

dystonia/parkinsonism. Patients identified by NGS
techniques account for a growing percentage of
newly identified patients, whose signs and symptoms
may or may not fit within the spectrum of previously
described phenotypes for AHC and RDP.
Despite the important observation that mutations in the ATP1A3 gene are a frequent cause of
both AHC and RDP, some individuals who meet
clinical diagnostic criteria for these syndromes will
not have evident pathogenic mutations in ATP1A3.
Studies continue to identify alternate molecular
etiologies in patients with well-defined AHC and
RDP phenotypes and for potentially valuable biomarkers that can distinguish between patients with
or without pathogenic mutations in ATP1A3. If
AHC is suspected clinically and an ATP1A3 mutation cannot be identified, consideration could be
given to then sequence individual genes or NGS
panels that include complete coverage for genes
associated with overlapping neurologic phenotypes
(table 3).
A medical genetics consultation is strongly recommended before pursuing whole-exome sequencing
(WES), a complex test with the potential for incidental findings that requires detailed pretest and posttest
counseling. When a diagnosis of AHC or RDP is not
previously suspected by the clinician, extra caution
should be used in the interpretation of previously
unreported or rare pathogenic mutations or variants
of unknown significance (VUSs), with care taken to
evaluate both the specific mutation and the symptoms of the patient for proper diagnosis along the
spectrum of ATP1A3-related disorders. Caution is
warranted because VUSs are very common in panel
testing and extremely common in WES. Consultation with a medical genetics professional familiar with
the evaluation of a VUS and with family studies can
aid in results interpretation, testing of family members, and genetic counseling.
ATP1A3-RELATED DISORDERS AND EPILEPSY

Approximately 50% of children with AHC also carry
a diagnosis of epilepsy,32–34 although the certainty of
this diagnosis can remain elusive because of similarity
of epileptic and nonepileptic paroxysmal events such
as dystonia, tremor, or paresis. By contrast, patients
with RDP have seizures as a rare comorbidity,20
although this manifestation may be underrecognized
as the number of patients with RDP is far less
than AHC.
Recently, the International League Against Epilepsy
revised the Operational Clinical Definition of Epilepsy
to allow for the diagnosis of epilepsy following a first
seizure in the context of increased recurrence risk.35
The challenge in accurately assessing the recurrence
risk in adults and children with ATP1A3-related

disorders is significant and may ultimately be dependent on specific genetic mutations.
Reviews of ATP1A3-related disorders have
emphasized the potentially catastrophic course of epilepsy in patients with AHC.32 For this reason, we
attempted to more precisely address seizure and
epilepsy-related clinical practice issues. It was agreed
that, when feasible, video-EEG characterization
should be obtained when new, distinct, and stereotyped events are noted. However, the abundance and
variability of paroxysmal events in AHC makes videoEEG characterization impractical for some instances.
Broad input from family members, caretakers, and
other medical personnel, as well as the use of personal
video capabilities, may aid in more accurately characterizing the events in question.
Routine EEG may provide limited benefit early in
the course of AHC evolution because classic epileptiform features are absent during most episodes.33 It is
unknown whether EEG may help to better assess
further risk of seizure later in the course of the disorder, when epilepsy is more typically present. Ultimately, workshop participants agreed that if clinical
suspicion is high and EEG features suggestive of an
underlying seizure tendency are noted, initiation of
an anticonvulsant medication is warranted. If the
EEG is unrevealing, then further clinical assessment
and video-EEG monitoring is reasonable.
DISCUSSION AND FUTURE DIRECTIONS ATP1A3related disorders have become increasingly recognized
with the advent of more potent molecular diagnostic
tools. However, substantial knowledge gaps remain in
understanding how specific genetic mutations and
other epigenetic phenomena might influence physiologic mechanisms to produce the variable phenotypes.
There is no specific treatment for ATP1A3-related
diseases other than symptomatic, although flunarizine
is widely used.36,37 There is no approved medication
or device that alters the underlying deficit in the
Na1/K1 pump.
During the course of workshop proceedings, it
became clear that considerable challenges remain. A
critical impediment to effective clinical trial design
is a lack of standardized language to capture and measure disease burden for paroxysmal symptoms in
AHC. Clinical trial designs typically implemented
in epilepsy are inadequate. Patients with ATP1A3related disorders also demonstrate variable impairments in cognition, language, mood, behavior, and
gross motor and fine motor functions, and these outcomes will also be important to effectively document
and assess reliably over time. Finally, development or
use of caregiver and patient-reported outcome tools
will likely prove a critical part of this process, especially if broader quality of life trends can be
Neurology: Genetics
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incorporated in addition to typical event counting.
This combination may in the end prove the most
effective way to measure improvement in response
to specific targeted interventions. Given the variable
phenotype, a multifaceted approach will be needed in
which outcome measures are carefully chosen to
reflect the most likely benefit of any intervention.
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